Palisade Bio, INC Form 4 insider transactions

Palisade Bio, Inc. Director Robert Baltera Jr. reported the acquisition of 45,000 shares of common stock through multiple transactions.

Robert Baltera Jr., a Director at Palisade Bio, Inc., has acquired a total of 50,000 shares of common stock through multiple transactions.

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, reported transactions involving the settlement of Restricted Stock Units and the subsequent sale of shares to cover tax obligations.

John David Finley, CEO and Director of Palisade Bio, Inc., reported transactions involving the acquisition and sale of company stock, including shares to cover tax withholding obligations.

Robert Baltera Jr., a Director at Palisade Bio, Inc., has acquired 30,000 shares of common stock through open market purchases.

Palisade Bio, Inc. Director Robert Baltera Jr. acquired 336,904 shares of common stock.

Director Binxian Wei acquired 612,500 shares of Palisade Bio common stock through RSU grants and vesting.

Director Donald Allen Williams acquired 1,559,566 shares of Palisade Bio, Inc. common stock through RSU grants and vesting.

Director Emil Chuang acquired 612,500 shares of Palisade Bio common stock through RSU grants and vesting.

Director Jordan Michael Zwick was granted 336,904 restricted stock units by Palisade Bio, Inc.

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, reported the vesting and subsequent sale of shares to cover tax obligations, while increasing overall beneficial ownership.

Palisade Bio CEO John David Finley reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, received a grant of 787,000 Restricted Stock Units, aligning executive incentives with shareholder value.

Palisade Bio's CEO and CFO, John David Finley, was granted 2,011,000 Restricted Stock Units, aligning executive incentives with shareholder value.

Palisade Bio Director Donald Allen Williams purchased 5,000 shares of common stock at $1.6712 per share, increasing his direct beneficial ownership.

Palisade Bio Director Donald Allen Williams purchased 5,000 shares of common stock at $1.88 per share.

Palisade Bio, Inc. filed an amended Form 4, significantly reducing Director Donald Allen Williams' Restricted Stock Unit grant from 1,538,700 to 182,000 units.

Palisade Bio, Inc. director Wei Binxian's previously reported Restricted Stock Unit grant has been significantly reduced from 510,700 to 60,600 units.

Palisade Bio, Inc. filed an amended Form 4 to correct a previously reported Restricted Stock Unit grant for Director Emil Chuang, reducing it from 510,700 to 60,600 RSUs.

Palisade Bio director Donald Allen Williams was granted 1,538,700 Restricted Stock Units, vesting over three years.

Palisade Bio, Inc. director Binxian Wei received an award of 510,700 Restricted Stock Units, aligning his interests with shareholders.

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, was granted 7.6 million Restricted Stock Units, vesting over approximately two years.

PALISADE BIO's CEO and CFO, John David Finley, was granted 9,179,400 Restricted Stock Units, vesting over approximately two years.

Palisade Bio, Inc. has granted Director Emil Chuang 510,700 Restricted Stock Units, which will vest over three years and may be settled in cash if equity is unavailable.

Palisade Bio, Inc. director Donald Allen Williams was granted 64,400 phantom units, which vest over three years and are cash-settled.

Palisade Bio's CEO and CFO, John David Finley, was granted 323,400 cash-settled phantom units, aligning executive incentives with future company performance.

Palisade Bio, Inc. Director Binxian Wei was granted 18,800 phantom units, equivalent to common stock, vesting over three years.

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, was granted 289,000 cash-settled phantom units vesting quarterly over three years.

Palisade Bio Inc. Director Emil Chuang was granted 18,800 phantom units, equivalent to common stock, vesting over three years.

Palisade Bio, Inc. Director Emil Chuang was granted 8,000 stock options with an exercise price of $0.7502 per share, vesting over three years.